Assessment of Reliability and Validity of SF-12v2 among a Diabetic Population

Kathe, Niranjan; Hayes, Corey J.; Bhandari, Naleen Raj; Payakachat, Nalin

doi:10.1016/j.jval.2017.09.007

Cited by 42 publications

(31 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MCS and PCS were very poorly related with each other. These findings were as expected and similar to those found by previous studies that validated the SF−12v2 using Medical Expenditure Panel Survey data, albeit in different populations [16,18,19]. Thus, the questionnaire demonstrated sufficient convergent and discriminant ability.…”

Section: Discussionsupporting

confidence: 90%

“…To examine the construct validity, we considered the convergent and discriminant validity and carried out confirmatory factor analysis. We tested for convergent and discriminant validity against the PHQ−2 scores, Kessler Index scores, and questions on perceived health and perceived mental health from the same round as MCS/PCS, using the Spearman rank correlation coefficients [18]. Coefficients with values less than 0.3 were considered poor, from 0.3 to 0.5 were considered fair, greater than 0.5 (up to 0.8) were considered moderately strong, and greater than 0.8 were considered very strong [37].…”

Section: Validitymentioning

confidence: 99%

“…The Medical Expenditure Panel Survey includes the SF−12v2 instrument [10]. Previous studies have used the SF−12v2 instrument to quantify health related quality of life in an older population [11][12][13][14][15] and although this instrument has been validated in other groups [16][17][18][19][20][21], there is a need to validate this instrument among older adults. This study aims to evaluate the psychometric properties of the SF−12v2 among older adults using data from the Medical Expenditure Panel Survey and classical testing methods.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Reliability and Validity of the Short-Form 12 Item Version 2 (SF−12v2) Health-Related Quality of Life Survey and Disutilities Associated with Relevant Conditions in the U.S. Older Adult Population

Shah

Brown

2020

JCM

View full text Add to dashboard Cite

This study aimed to validate the Short-Form 12-Item Survey—version 2 (SF−12v2) in an older (≥65 years old) US population as well as estimate disutilities associated with relevant conditions, using data from the Medical Expenditure Panel Survey longitudinal panel (2014–2015). The physical component summary (PCS) and mental component summary (MCS) scores were examined for reliability (internal consistency, test-retest), construct validity (convergent and discriminant, structural), and criterion validity (concurrent and predictive). The study sample consisted of 1040 older adults with a mean age of 74.09 years (standard deviation: 6.19) PCS and MCS demonstrated high internal consistency (Cronbach’s alpha—PCS: 0.87, MCS: 0.86) and good and moderate test-retest validity, respectively (intraclass correlation coefficient: PCS:0.79, MCS:0.59)). The questionnaire demonstrated sufficient convergent and discriminant ability. Confirmatory factor analysis showed adequate fit with the theoretical model and structural validity (goodness of fit = 0.9588). Concurrent criterion validity and predictive criterion validity were demonstrated. Activity limitations, functional limitations, arthritis, coronary heart disease, diabetes, myocardial infarction, stroke, angina, and high blood pressure were associated with disutilities of 0.18, 0.15, 0.06, 0.07, 0.07, 0.06, 0.09, 0.06, and 0.08, respectively, and demonstrated the responsiveness of the instrument to these conditions. The SF−12v2 is a valid and reliable instrument in an older US population.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Validitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reliability and Validity of the Short-Form 12 Item Version 2 (SF−12v2) Health-Related Quality of Life Survey and Disutilities Associated with Relevant Conditions in the U.S. Older Adult Population

Shah

Brown

2020

JCM

View full text Add to dashboard Cite

show abstract

“…SF-12v2’s brevity is an advantage in assessing older adults’ HRQoL in large-scale studies, resulting in less burden for respondents and researchers (7). SF-12v2 is a reliable, valid measure in a variety of population groups (6, 8–12), but information regarding its psychometric properties among older adults in China is still lacking. Two recent studies in Hong Kong have demonstrated validity and reliability for the general population and adolescents there (6, 13).…”

Section: Introductionmentioning

confidence: 99%

The Reliability and Validity of Short Form-12 Health Survey Version 2 for Chinese Older Adults

Su¹,

Wang²

2020

ijph

View full text Add to dashboard Cite

Background: We assessed the information regarding the psychometric properties of the Short Form-12 Health Survey Version 2 (SF-12v2) among older adults in China Methods: A cross-sectional study was conducted on a stratified representative sample of older adults (≥60 years) residing in community and nursing home settings in 2017-18. Reliability was estimated using the internal consistency method. Validity was assessed using convergent and discriminant validity checks, factor analyses (including both exploratory and confirmatory factor analyses [EFA and CFA]), and “known groups” construct validity. Results: The final sample comprised 1000 older adults (451 community-dwelling and 549 institutional). Cronbach’s α was 0.81 for the Physical Component Summary (PCS) and 0.83 for the Mental Component Summary (MCS), showing satisfactory internal consistency for both. Most items were strongly correlated with their represented component (Spearman’s correlation coefficient: 0.62–0.87), although the correlation of SF items with PCS was a bit stronger than that with MCS. A two-factor structure (physical and mental health) indicated by EFA jointly accounted for 68.50% of the variance and presented adequate goodness-of-fit indices (GFI=0.98, AGFI=0.92, RMSEA=0.08, 90% Cl RMSEA=0.06 to 0.11, NFI=0.98, and CFI=0.98) in CFA. Known-groups comparison showed that SF-12v2 summary scores did well in differentiating subgroups of older adults by age, marital status, and self-reported health problems (P≤0.05). Conclusion: SF-12v2 is a reliable and valid health-related quality of life instrument for Chinese older adults that works equally well with older adults under institutional care and community-based home care models.

show abstract

“…The current study finds that a substantial proportion of patients initiating SGLT2i metformin dual therapy are not at glycemic goal, which is consistent with data from the National Health and Nutrition Examination Surveys (NHANES), which reported that 22% of T2DM patients did not meet glycemic targets(ref) of HbA1C <8% 26 . Prolonged loss of glycemic control increases the risk of hospitalization, mortality, MACE 27,28 As patient's comorbidity burden increases it can lead to increased healthcare utilization and cost and worsen patient's quality of life [29][30][31][32] . Furthermore, patients should be made aware that adherence to prescribed medication is an important factor for improved outcomes and general wellbeing.…”

Section: Discussionmentioning

confidence: 99%

Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium–glucose cotransporter 2 inhibitor: a retrospective database study

Lautsch

Iglay

Yang

et al. 2020

Current Medical Research and Opinion

Self Cite

View full text Add to dashboard Cite

Objective: To assess the level of glycemic control among type 2 diabetes patients on sodium-glucose cotransporter 2 inhibitor (SGLT2i) and metformin dual therapy. Methods: Observational, retrospective database study in adult type 2 diabetes mellitus patients from the IQVIA Electronic Medical Record (EMR) database was conducted. The observation period was June 2015 to June 2018. Patient's earliest encounter in the observation period while on SGLT2i and metformin dual therapy served as the index date. Patients were required to have at least one HbA1c measure in the 12 months prior to the index date and be on SGLT2i and metformin dual therapy and no other antihyperglycemic treatment as of the HbA1c measurement date or any time during the 90 days prior. The associations between sociodemographic factors and clinical burden on achievement of HbA1c <8% were assessed using multivariable logistic regression with backward stepwise selection. Results: Of 3491 patients, 2176 (62.3%) achieved HbA1c <8%, with a median distance to goal of 1.1% (IQR 0.5-2.3%) for those not at glycemic target. Mean age was 56.5 years and 52.6% were male. At baseline, 28.3% of patients had established cardiovascular disease/chronic kidney disease, and of those 63.8% had HbA1c <8%. African American patients had lower odds of attaining HbA1c <8% when compared with white patients [OR 0.69], while older patients had marginally higher odds [OR 1.01]. Conclusion: Approximately 3 out of 5 patients on metformin and SGLT2i dual therapy achieved HbA1c <8%, with African Americans having a lower likelihood of achieving this glycemic goal.

show abstract

Assessment of Reliability and Validity of SF-12v2 among a Diabetic Population

Abstract: The SF-12v2 is a valid generic instrument for measuring quality of life in diabetic patients.

Cited by 42 publications

References 32 publications

Reliability and Validity of the Short-Form 12 Item Version 2 (SF−12v2) Health-Related Quality of Life Survey and Disutilities Associated with Relevant Conditions in the U.S. Older Adult Population

Reliability and Validity of the Short-Form 12 Item Version 2 (SF−12v2) Health-Related Quality of Life Survey and Disutilities Associated with Relevant Conditions in the U.S. Older Adult Population

The Reliability and Validity of Short Form-12 Health Survey Version 2 for Chinese Older Adults

Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium–glucose cotransporter 2 inhibitor: a retrospective database study

Contact Info

Product

Resources

About